Extended-Release Niacin

DRUG2 trials

Sponsors

Hannover Medical School, Henry Ford Health System

Conditions

Ischemic StrokeMetabolic Syndrome

Phase 2

Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery

TerminatedNCT00796887

Henry Ford Health SystemIschemic Stroke

Start: 2009-04-01End: 2012-08-01Updated: 2026-08-28

Phase 4

The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)

CompletedNCT00346970

Hannover Medical SchoolMetabolic Syndrome

Start: 2006-07-31End: 2007-07-31Updated: 2008-05-06

Related Papers

Abstract WP156: A Phase IIa Double-blind, Placebo Controlled Study of Extended-release Niacin for Stroke Recovery

Stroke2018-01-224 citations

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.

2009-12-21278 citations